Argenx price target lowered to $468 from $471 at JMP Securities

JMP Securities lowered the firm’s price target on Argenx to $468 from $471 and keeps an Outperform rating on the shares. Argenx reported Q1 results that were above consensus expectations on the top line, and regulatory progress for VYVGART remainson track for further geographic expansion, with multiple global submissions under review and expected to be completed in generalized Myasthenia Gravis and chronic inflammatory demyelinating polyneuropathy this year, the analyst tells investors in a research note. The firm sees multiple catalysts in 2024, including full Phase 2 results of empasiprubart in multifocal motor neuropathy.